The companies will use novel screening tools, including systems-biology approaches and technologies developed at Sanford-Burnham, with
the aim of discovering new therapeutic strategies for reducing insulin resistance in obesity and diabetes
With several papers published recently that provide new information about the genetics behind Down syndrome or how to reverse some of its cognitive effects,
a team of researchers from the Sanford-Burnham Medical Research Institute are throwing their hats into the ring with a study describing how the extra
chromosome inherited in the congenital disorder alters brain and body development
In a
study published Feb. in the Elsevier journal Cell, the Sanford-Burnham team demonstrates how the transcription factor ATF2, which is associated with poor
prognosis in melanoma, elicits oncogenic activities in melanoma and tumor suppressor activities in nonmalignant skin cancer
Partnership aligns complementary strengths in biomedical research, clinical research and drug development to
identify and validate obesity-related biomarkers and new peripheral molecular targets of mutual interest
Team
shows in genome-wide study how key immune sensors arrive at the 'front lines' of infection and say this knowledge could one day be exploited to develop new
therapies for infectious and autoimmune diseases with significant unmet medical need, such as lupus and inflammatory bowel disease.
Team’s results suggest CDP138 is a key molecule linking the Akt2 pathway to the regulation of GLUT4
vesicle/plasma membrane fusion, but most importantly, the finding greatly enhances our understanding of glucose metabolism, which contributes to the
development of type 2 diabetes
We’ve updated our Privacy Policy to make it clearer how we use your personal data. Please read our Cookie Policy to learn how we use cookies to provide you with a better experience.